: The controlling shareholder intends to reduce its holdings in the company by no more than 2.04%.

On September 29, Erkang Pharmaceuticals announced that its controlling shareholder Shuai Fangwen, who holds 41.38% of the company's shares, plans to reduce his holdings by a total of no more than 42 million shares within 3 months after 15 trading days, using centralized bidding or block trading methods, which is equivalent to no more than 2.04% of the company's total share capital.